HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Nonprofit Pharmaceutical Companies

555.407

-19.420-3.38%

Number of Gainers:3

Number of Losers:28

Number of Flat:3

PE:- -

High:575.370

Open:574.827

Low:551.244

Close:574.827

Volume:75.91M

Turnover:1.57B

Market Cap:345.95B

Float Cap:310.09B

Loading ...

EVEREST MED Shareholders Pass Key Commercialization Agreements at Special Meeting

CMS Receives NMPA Acceptance and Priority Review for Ruxolitinib Cream's Atopic Dermatitis Application

Everest Medicines Ltd. Held Extraordinary General Meeting

Hengrui Pharma's Novel Drug SHR-1918 Injection Receives Marketing Application Acceptance and Priority Review Status

CANSINOBIO's Meningococcal Vaccine Menhycyte™ Receives Expanded Age Indication Approval

AH Premium Rankings for February 24th

Zhejiang Medicine to Invest in Partnership Fund Targeting Silver Economy and Healthcare Sector

HBM Holdings (SEHK:2142) Valuation After Solstice Oncology Partnership On HBM4003 Rights Outside Greater China

Simply Wall St.

Job Opportunities Announced in Tianfu New Area and Jinniu District

Assessing CARsgen Therapeutics Holdings (SEHK:2171) Valuation After New CAR T-Cell Manufacturing Partnership

Simply Wall St.

A Look At InnoCare Pharma (SEHK:9969) Valuation As Dermatology Trials For Soficitinib Progress

Simply Wall St.

CStone Pharmaceuticals-B Shares Climb Over 5% Following UK Regulatory Approval for Sugemalimab's New Lung Cancer Indication

Domestic Innovative Drug BD Transaction Value Ranks First Globally, This ETF Secures Early Position

Medical Device Firms Emerge as Key Players in A-Share Market

Ascentage Pharma to Participate in Three Upcoming Investor Conferences

EDDING GENOR (06998) Allocates HK$1.461 Million for Share Buyback on February 23

Edding Genor Group Holdings files HKEX next-day disclosure return reporting 457,500-share repurchase at HKD 3.19343 per share

BUZZ-HK-listed HBM jumps on licensing deal with Solstice on oncology drug

HBM HOLDINGS-B Shares Surge Over 8% in Morning Session on Major Global Licensing Deal for Next-Generation Antibody

CStone Pharma-B's PD-L1 Antibody Sugemalimab Gains UK Approval for Advanced Lung Cancer

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"Tiger Brokers,U.S. stock trading,Hong Kong stock trading,trading U.S. stocks,stock information,stock prices,U.S. stock quotes,U.S. stock trading,Hong Kong stock trading,IPO trading,buying U.S. stocks,global investment","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BK1574/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"BK1574","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","market":"HK","secType":"PLATE","nameCN":"Nonprofit Pharmaceutical Companies","latestPrice":555.40704,"timestamp":1771920487216,"preClose":574.827,"halted":0,"volume":75912636,"delay":0,"changeRate":-0.033784,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Closed","change":-19.419983,"latestTime":"02-24 16:00:00","open":574.827,"high":575.3701,"low":551.2441,"amount":1574615994,"amplitude":0.041971,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1771983000000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1771896600000,1771905600000],[1771909200000,1771920000000]],"pbRate":5.026953,"peRate":-40.55114,"turnoverRate":0.002847,"increases":2,"decrements":30,"flats":0,"marketCap":345950625792,"floatMarketCap":310085645232},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","high":575.3701,"amplitude":0.041971,"preClose":574.827,"low":551.2441,"pbRate":"5.026953","latestPrice":555.40704,"volume":75912636,"delay":0,"open":574.827,"prevYearClose":556.26263,"prevWeekClose":571.129,"prevMonthClose":555.241,"prevQuarterClose":556.263,"fiveDayClose":551.442,"twentyDayClose":569.48,"sixtyDayClose":594.047,"secType":"PLATE","market":"HK","turnoverRate":0.002847,"peRate":-40.55114,"marketCap":345950625792,"floatMarketCap":310085645232,"timestamp":1771920487216,"nameCN":"Nonprofit Pharmaceutical Companies"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1574\",,,,undefined,":{"bkCode":"BK1574","up":3,"down":28,"flat":3},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1574\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1121333319","title":"EVEREST MED Shareholders Pass Key Commercialization Agreements at Special Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=1121333319","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1121333319?lang=en_us&edition=fundamental","pubTime":"2026-02-24 18:08","pubTimestamp":1771927696,"startTime":"0","endTime":"0","summary":"EVEREST MED (01952) announced the successful conclusion of its Special General Meeting held virtually on February 24, 2026, where all proposed resolutions were formally approved by shareholders....","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1574","01952","BK1583"],"gpt_icon":0},{"id":"1104875656","title":"CMS Receives NMPA Acceptance and Priority Review for Ruxolitinib Cream's Atopic Dermatitis Application","url":"https://stock-news.laohu8.com/highlight/detail?id=1104875656","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1104875656?lang=en_us&edition=fundamental","pubTime":"2026-02-24 17:52","pubTimestamp":1771926741,"startTime":"0","endTime":"0","summary":"CMS announced that its subsidiary, Demai Pharmaceutical, a specialist in dermatological health currently pursuing an independent listing on the Main Board of the Hong Kong Stock Exchange, has...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BVYPNQ40.USD","AD","IE00BYV24P56.USD","LU2488822045.USD","SG9999015945.SGD","IE00BGHQDM52.EUR","SG9999015978.USD","06978","BK4132","IE00BVYPNP33.GBP","BK1161","BK1574","SG9999015986.USD","BK1593","IE00BMCWC346.EUR","BK1191","00867","SG9999015952.SGD","SG9999004220.SGD","159992"],"gpt_icon":0},{"id":"2613879629","title":"Everest Medicines Ltd. Held Extraordinary General Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2613879629","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613879629?lang=en_us&edition=fundamental","pubTime":"2026-02-24 17:03","pubTimestamp":1771923827,"startTime":"0","endTime":"0","summary":"Everest Medicines Ltd. held an extraordinary general meeting on Feb. 24, 2026. Shareholders approved the Commercialization Service Agreement and related transactions, approved a grant of awards to Mr. Yifang Wu under the Pre-IPO ESOP, approved and adopted the 2026 Share Scheme with a 10% scheme mandate limit, and approved and adopted a 0.5% service provider sublimit under the 2026 Share Scheme.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Everest Medicines Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on February 24, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nNDL43k2db:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01952","BK1583","BK1161","BK1574"],"gpt_icon":0},{"id":"1189255692","title":"Hengrui Pharma's Novel Drug SHR-1918 Injection Receives Marketing Application Acceptance and Priority Review Status","url":"https://stock-news.laohu8.com/highlight/detail?id=1189255692","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1189255692?lang=en_us&edition=fundamental","pubTime":"2026-02-24 16:53","pubTimestamp":1771923195,"startTime":"0","endTime":"0","summary":"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (600276.SH) announced that its subsidiary, Beijing Shengdi Pharmaceutical Co., Ltd., recently received a Notice of Acceptance from the National Medical...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1255011170.USD","LU1655091616.SGD","LU0405327148.USD","LU1328615791.USD","LU1997244956.HKD","159992","LU0359201612.USD","LU1997245177.USD","LU2097828557.USD","LU1023057109.AUD","BK1161","LU1064130708.USD","BK1191","06978","LU1580142542.USD","LU2580892862.HKD","LU2488822045.USD","600276","BK0183","LU2580892789.USD","LU1781817850.SGD","BK0188","01276","LU2097828474.EUR","LU1064131003.USD","LU2495084118.USD","LU2097828631.EUR","LU2328871848.SGD","LU1146622755.USD","BK0028","LU1997245094.SGD","LU2543165471.USD","BK0012","BK0239","BK1574","LU0359202008.SGD","BK0196","BK0060","LU2097828805.USD","LU1820825898.SGD","LU2148510915.USD","LU0405327494.USD","LU2289578879.USD","LU1969619763.USD","LU0359201885.HKD","LU2097828714.EUR"],"gpt_icon":0},{"id":"1159534204","title":"CANSINOBIO's Meningococcal Vaccine Menhycyte™ Receives Expanded Age Indication Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=1159534204","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1159534204?lang=en_us&edition=fundamental","pubTime":"2026-02-24 16:46","pubTimestamp":1771922808,"startTime":"0","endTime":"0","summary":"CANSINOBIO (06185) announced that it has received a Supplemental Drug Application Approval Notice from the National Medical Products Administration (NMPA). According to the notice, the NMPA has...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1191","BK1574","BK1515","06185"],"gpt_icon":0},{"id":"1179077937","title":"AH Premium Rankings for February 24th","url":"https://stock-news.laohu8.com/highlight/detail?id=1179077937","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1179077937?lang=en_us&edition=fundamental","pubTime":"2026-02-24 16:21","pubTimestamp":1771921291,"startTime":"0","endTime":"0","summary":"As of the market close on February 24th, NE ELECTRIC (00042), JINGCHENG MAC (00187), and Sinopec Oilfield Service (01033) recorded the highest AH share premium rates, at 757.14%, 285.62%, and 282.18%...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1105","HK0000352382.USD","LU0348788117.USD","LU0043850808.USD","LU1211504680.USD","LU0516423174.USD","LU0531970944.HKD","LU0348827113.USD","LU0502904849.HKD","LU1282649810.SGD","BK1552","LU1152091168.USD","IE0031814852.USD","LU1008478684.HKD","BK1515","LU0163747925.USD","LU2153592121.USD","LU0266512473.USD","LU0823039010.USD","IE00BVYPNQ40.USD","SG9999002463.SGD","LU0819121731.USD","BK1543","LU0588545730.USD","LU0572940350.SGD","IE00B0169L03.USD","LU0469268626.HKD","LU0634319403.HKD","LU0181495838.USD","LU0143863784.USD","IE00B3M56506.USD","HK0000306685.HKD","BK1231","BK1562","LU2399975544.HKD","00042","BK1140","LU0456827905.SGD","IE00BYV24P56.USD","IE00B031HY20.USD","LU1880383366.USD","LU0289960550.SGD","LU0821914370.USD","LU0096374516.USD","LU0084288322.USD","LU0329678170.USD","002594","BK1229","LU0164865239.USD","LU2476274720.SGD","LU0320764599.SGD","LU2097828714.EUR","BK1191","LU1868838027.USD","LU0823426308.USD","IE00BZ08YT58.USD","81211","LU0214875030.USD","LU0865486749.SGD","LU0269904917.USD","BK1550","LU0348735423.USD","LU0039217434.USD","LU0266512127.USD","LU0370786039.SGD","LU0594300179.USD","LU0856984785.SGD","LU0880133367.SGD","LU2360107325.USD","LU1769817179.HKD","LU2039709279.SGD","LU0164880469.USD","LU1880383440.USD","399300","BYDDY","LU2097828474.EUR","HYDD.SI","LU0511384066.AUD","SG9999014674.SGD","LU1960683339.HKD","HK0000306701.USD","BK1592","LU0359201612.USD","LU0516422440.USD","LU2778985437.USD","LU0149721374.USD","LU0594300419.USD","SG9999006514.SGD","LU0979878070.USD","LU0229945570.USD","LU1188198961.HKD","LU0620787316.HKD","LU0164939612.USD","BK1537","LU0456854461.SGD","LU0455707207.USD","LU1328277881.USD","LU0488056044.USD","LU0417516571.SGD","LU0348783233.USD","LU0868486357.SGD","BK1223","BK1183","LU0543330566.HKD","SG9999002828.SGD","LU0456846285.SGD","LU0737861772.HKD","LU0211977185.USD","IE00BZ08YR35.GBP","LU0254981946.USD","IE00BF5LJ272.USD","BK1237","BK1563","LU0708995583.HKD","LU0231483743.USD","BK1540","LU0588546209.SGD","LU0791591158.USD","BK1184","LU0051755006.USD","BK1507","LU0106959298.USD","LU1224709979.USD","LU0828238088.HKD","00187","LU0886674414.USD","LU2097828557.USD","LU0431992006.USD","LU0328353924.USD","BK1528","BK1174","LU1366334651.USD","LU0259732245.USD","LU0359201885.HKD","BK1163","LU0244354667.USD","BK1202","LU0505663152.USD","BK1224","LU0052750758.USD","IE0034224299.USD","LU1808992512.USD","LU0540923850.HKD","LU0588545904.SGD","LU2125910500.SGD","LU1720050803.USD","LU0048580855.USD","BK1198","LU0890818403.SGD","LU0348825331.USD","LU0348784397.USD","LU0823414478.USD","LU2097828631.EUR","LU0359202008.SGD","LU0509642566.USD","HK0000320223.HKD","BK1171","BK1583","LU1868837565.USD","LU0516422366.SGD","LU1105468828.SGD","LU0791590937.USD","BK1522","LU2506951792.HKD","LU0326950275.SGD","IE00B031J352.USD","LU0593848301.USD","LU0165289439.USD","LU0314109678.HKD","IE00B543WZ88.USD","LU0327786744.USD","BK1576","LU0918141887.USD","LU0264606111.USD","LU0287142896.SGD","LU0737861699.HKD","BK1214","LU0516423091.SGD","LU1675838814.USD","LU1961090484.USD","LU2357125470.USD","LU0067412154.USD","LU2045819591.USD","LU1719994722.HKD","LU0329678337.USD","LU0823414551.USD","LU0307460666.USD","LU1794554557.SGD","159982","BK1112","LU0417516902.SGD","LU1366334578.USD","BK1521","LU0828237940.HKD","BK1560","LU0640798160.USD","LU0449509016.USD","LU1048596156.SGD","LU1251922891.USD","LU0561508036.HKD","LU0650527681.SGD","LU0315178854.USD","IE00BPRC5H50.USD","BK1610","LU1831875114.USD","BK1546","IE0008369823.USD","LU0589944569.HKD","LU0228367735.SGD","LU1813983027.USD","LU0516422952.EUR","BK1135","LU1303224171.USD","BK1594","LU0082770016.SGD","LU0572944931.SGD","03143","BK1582","LU3063872942.SGD","IE00BD6J9T35.USD","LU0117841782.USD","LU0871576103.HKD","LU0449515922.USD","LU0348805143.USD","BK1564","LU0588545490.SGD","LU0823426480.USD","LU0164872284.USD","LU0345780521.USD","LU1226287529.USD","HK0000320264.USD","LU2348774022.SGD","LU1861219969.SGD","LU0049853897.USD","IE00BVYPNP33.GBP","LU0572939691.SGD","BK1554","LU1242518931.SGD","LU0348816934.USD","LU0072913022.USD","LU1770034418.SGD","BK1509","LU1993786604.SGD","LU2449936058.SGD","SG9999015986.USD","BK1149","BK1551","BK1205","BK1544","LU1688375341.USD","LU0648948544.HKD","BK1258","LU0828237510.HKD","LU0862451753.SGD","600860","LU1481107354.HKD","LU0061477393.USD","SG9999001226.SGD","LU1152091754.HKD","LU2249611893.SGD","IE00BGHQDM52.EUR","SG9999004220.SGD","IE00B29SXG58.USD","LU0501845795.SGD","LU0082770016.USD","BK1584","LU1504937902.USD","SG9999015978.USD","BK1503","LU0823038988.USD","LU1282649067.USD","BK1574","LU1807302812.USD","LU2294711713.HKD","LU0228659784.USD","IE0008368742.USD","LU0143863198.USD","BK1119","SG9999015945.SGD","BK1161","LU0054450605.USD","LU0531971595.HKD","IE00BZ08YS42.EUR","LU1282648689.USD","LU1023057109.AUD","LU1769817096.USD","LU0140636845.USD","LU0175139822.USD","LU0797268264.HKD","LU0463099449.HKD","LU0605514214.HKD","LU1046422090.SGD","LU1115378108.SGD","LU1868837722.USD","LU0289739343.SGD","BK1147","LU0289961442.SGD","BK1116","LU0345780281.USD","BK1501","LU2097828805.USD","LU2226246903.HKD","IE00BMCWC346.EUR","IE00B5MMRT66.SGD","LU2476274308.USD","BK1505","LU1282649141.HKD","LU1242518857.USD","LU0819123356.HKD","LU0417516738.SGD","BK1514","LU0384037296.USD","LU0348814723.USD","LU0315179316.USD","HK0000352291.HKD","BK1539","LU2242644610.SGD","LU0106252389.USD","SG9999015952.SGD","BK1240","LU0173614495.USD","SG9999006597.SGD","LU1861214812.USD","LU0918141705.HKD","BK1141"],"gpt_icon":0},{"id":"1152132520","title":"Zhejiang Medicine to Invest in Partnership Fund Targeting Silver Economy and Healthcare Sector","url":"https://stock-news.laohu8.com/highlight/detail?id=1152132520","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1152132520?lang=en_us&edition=fundamental","pubTime":"2026-02-24 15:57","pubTimestamp":1771919826,"startTime":"0","endTime":"0","summary":"Zhejiang Medicine Co.,Ltd. (600216.SH) announced that on February 24, 2026, the company signed a partnership agreement with general partner CITIC Healthcare Equity Investment Private Fund Management...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["159938","BK0028","BK1515","BK0239","09939","600216","BK0188","BK0191","BK1574","BK1161"],"gpt_icon":0},{"id":"2613046793","title":"HBM Holdings (SEHK:2142) Valuation After Solstice Oncology Partnership On HBM4003 Rights Outside Greater China","url":"https://stock-news.laohu8.com/highlight/detail?id=2613046793","media":"Simply Wall St.","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613046793?lang=en_us&edition=fundamental","pubTime":"2026-02-24 15:32","pubTimestamp":1771918325,"startTime":"0","endTime":"0","summary":"HBM Holdings (SEHK:2142) shares have been in focus after the company signed an exclusive license and equity partnership with Solstice Oncology, centered on its clinical asset HBM4003 outside Greater China.\nSee our latest analysis for HBM Holdings.\nThe Solstice agreement arrives as momentum in HBM Holdings' shares has picked up again, with a 1 day share price return of 4.41% and 7 day share price return of 8.12%, while the 1 year total shareholder return of 123.82% and 3 year total shareholder...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2142/hbm-holdings-shares/news/hbm-holdings-sehk2142-valuation-after-solstice-oncology-part","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2142/hbm-holdings-shares/news/hbm-holdings-sehk2142-valuation-after-solstice-oncology-part","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["HBM","BK1574","BK1161","BK1583","02142","DCF","BK4168"],"gpt_icon":0},{"id":"1149792548","title":"Job Opportunities Announced in Tianfu New Area and Jinniu District","url":"https://stock-news.laohu8.com/highlight/detail?id=1149792548","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1149792548?lang=en_us&edition=fundamental","pubTime":"2026-02-24 14:45","pubTimestamp":1771915512,"startTime":"0","endTime":"0","summary":"Job seekers are advised to take note of multiple recruitment drives currently underway. Sichuan Tianfu New Area has announced numerous corporate job openings, while Jinniu District is hiring eight...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","09996","BK1222","09997","BK1100","BK1583"],"gpt_icon":0},{"id":"2613793010","title":"Assessing CARsgen Therapeutics Holdings (SEHK:2171) Valuation After New CAR T-Cell Manufacturing Partnership","url":"https://stock-news.laohu8.com/highlight/detail?id=2613793010","media":"Simply Wall St.","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613793010?lang=en_us&edition=fundamental","pubTime":"2026-02-24 12:51","pubTimestamp":1771908706,"startTime":"0","endTime":"0","summary":"CARsgen Therapeutics Holdings (SEHK:2171) has entered new cooperation agreements to build a commercial CAR T-cell manufacturing base in Shanghai’s Jinshan District, supporting its existing therapies, late-stage candidates and future allogeneic products.\nSee our latest analysis for CARsgen Therapeutics Holdings.\nThe cooperation news lands as CARsgen’s share price sits at HK$16.14, with a 1-day share price return of 3.33% and 7-day share price return of 7.10%. The 1-year total shareholder...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2171/carsgen-therapeutics-holdings-shares/news/assessing-carsgen-therapeutics-holdings-sehk2171-valuation-a","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2171/carsgen-therapeutics-holdings-shares/news/assessing-carsgen-therapeutics-holdings-sehk2171-valuation-a","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4022","BK4007","BK1587","BK4139","BK1574","LENZ","BK4539","02171","CAR","BK4230","BK1585","BK1161"],"gpt_icon":0},{"id":"2613176599","title":"A Look At InnoCare Pharma (SEHK:9969) Valuation As Dermatology Trials For Soficitinib Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2613176599","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613176599?lang=en_us&edition=fundamental","pubTime":"2026-02-24 11:28","pubTimestamp":1771903681,"startTime":"0","endTime":"0","summary":"InnoCare Pharma (SEHK:9969) has drawn fresh investor attention after dosing the first patient in a Phase II/III trial of TYK2 inhibitor soficitinib for chronic spontaneous urticaria, alongside progress across multiple late stage dermatology programs.\nSee our latest analysis for InnoCare Pharma.\nThe new dermatology trial news comes after a mixed price patch, with a 7.71% 1 month share price return and a 1 year total shareholder return of 63.92%, even though the 90 day share price return shows...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9969/innocare-pharma-shares/news/a-look-at-innocare-pharma-sehk9969-valuation-as-dermatology","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9969/innocare-pharma-shares/news/a-look-at-innocare-pharma-sehk9969-valuation-as-dermatology","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1574","BK4097","PRGS","09969","BK1161","LU2065732104.USD"],"gpt_icon":0},{"id":"1161661386","title":"CStone Pharmaceuticals-B Shares Climb Over 5% Following UK Regulatory Approval for Sugemalimab's New Lung Cancer Indication","url":"https://stock-news.laohu8.com/highlight/detail?id=1161661386","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1161661386?lang=en_us&edition=fundamental","pubTime":"2026-02-24 10:36","pubTimestamp":1771900611,"startTime":"0","endTime":"0","summary":"CStone Pharmaceuticals-B (02616) rose more than 5% in Hong Kong trading. At the time of writing, the stock was up 5.12% to HK$6.36, with a turnover of HK$23.93 million. The increase follows the...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VXUS","BK4585","BK4588","BK4134","BK1574","VT","02616","BK1161","III"],"gpt_icon":0},{"id":"1147442940","title":"Domestic Innovative Drug BD Transaction Value Ranks First Globally, This ETF Secures Early Position","url":"https://stock-news.laohu8.com/highlight/detail?id=1147442940","media":"Deep News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1147442940?lang=en_us&edition=fundamental","pubTime":"2026-02-24 08:51","pubTimestamp":1771894296,"startTime":"0","endTime":"0","summary":"In recent years, the biotechnology industry has entered a phase of rapid growth, becoming a key sector driving global technological revolution and industrial transformation, continuously attracting...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["159992","06978","BK1161","BK4550","BK1574","BK4588","BK4585","FDN"],"gpt_icon":0},{"id":"1127447506","title":"Medical Device Firms Emerge as Key Players in A-Share Market","url":"https://stock-news.laohu8.com/highlight/detail?id=1127447506","media":"Deep News","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1127447506?lang=en_us&edition=fundamental","pubTime":"2026-02-24 06:52","pubTimestamp":1771887138,"startTime":"0","endTime":"0","summary":"This year, the A-share market has welcomed 16 new listings, with medical device companies accounting for four of them, marking a notable highlight in the IPO market at the start of the year. Among...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["159883","BK1583","09997","399300","BK1222","BK1574","BK1100","09996","159982"],"gpt_icon":0},{"id":"2613784767","title":"Ascentage Pharma to Participate in Three Upcoming Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2613784767","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613784767?lang=en_us&edition=fundamental","pubTime":"2026-02-23 21:00","pubTimestamp":1771851652,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascentage Pharma Group International published the original content used to generate this news brief via GlobeNewswire  on February 23, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260223:nNDL8237Kb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2095319765.USD","SG9999014039.USD","SG9999014013.SGD","BK4112","SG9999014021.USD","IE00B64PRP62.GBP","IE00BGHQF748.EUR","LU2210150020.SGD","BK1161","IE00BKPKM429.USD","LU0314104364.USD","IE00B3QW5Z07.USD","BK4585","SG9999014005.SGD","LU2210149790.SGD","BK4588","06855","BK1574","NDAQ"],"gpt_icon":0},{"id":"1182045646","title":"EDDING GENOR (06998) Allocates HK$1.461 Million for Share Buyback on February 23","url":"https://stock-news.laohu8.com/highlight/detail?id=1182045646","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1182045646?lang=en_us&edition=fundamental","pubTime":"2026-02-23 19:00","pubTimestamp":1771844413,"startTime":"0","endTime":"0","summary":"EDDING GENOR (06998) announced that on February 23, 2026, the company repurchased 457,500 shares at a total cost of HK$1.461 million. The buyback price ranged from HK$3.17 to HK$3.20 per share.","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","06998","BK1583","BK1574"],"gpt_icon":0},{"id":"2613785731","title":"Edding Genor Group Holdings files HKEX next-day disclosure return reporting 457,500-share repurchase at HKD 3.19343 per share","url":"https://stock-news.laohu8.com/highlight/detail?id=2613785731","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613785731?lang=en_us&edition=fundamental","pubTime":"2026-02-23 18:53","pubTimestamp":1771844018,"startTime":"0","endTime":"0","summary":"Edding Genor Group Holdings files HKEX next-day disclosure return reporting 457,500-share repurchase at HKD 3.19343 per share. Edding Genor Group Holdings Ltd.  filed a next day disclosure return with HKEX reporting that it repurchased 457,500 ordinary shares on 23 February 2026 to be held as treasury shares. The shares were bought on-market at a volume-weighted average price of about HK$3.19 per share , for an aggregate consideration of HK$1,460,995.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Edding Genor Group Holdings Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on February 23, 2026, and is solely responsible for the infor","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260223:nNDL7W75mv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1574","06998","BK1583"],"gpt_icon":0},{"id":"2613440208","title":"BUZZ-HK-listed HBM jumps on licensing deal with Solstice on oncology drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2613440208","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613440208?lang=en_us&edition=fundamental","pubTime":"2026-02-23 10:22","pubTimestamp":1771813359,"startTime":"0","endTime":"0","summary":"BUZZ-HK-listed HBM jumps on licensing deal with Solstice on oncology drug ** Shares of HBM Holdings 2142.HK jump 9.3% to HK$13.38, their highest level since January 20, and on course for a third straight session of gains** Stock of the Chinese immuno-oncology and immunology diseases therapeutics developer on track for biggest one-day pct gain since August 29** HBM says it has agreed to grant Solstice Oncology - a clinical-stage biotechnology firm set up by venture capital investors, an exclusive license to develop and commercialise a clinical-stage portfolio asset for tumors treatment HBM4003  outside Greater China  ** HBM is eligible to receive upfront consideration valued at $105 million, comprising an upfront cash payment of $50 million, a near-term cash payment of $5 million, and over $50 million of equity interest in Solstice Oncology to be issued and allotted to the company** HBM is also eligible to receive regulatory and commercial milestone payments of up to $1.1 billion on the","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260223:nL1N3ZJ014:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1574","02142","BK1583"],"gpt_icon":0},{"id":"1158828817","title":"HBM HOLDINGS-B Shares Surge Over 8% in Morning Session on Major Global Licensing Deal for Next-Generation Antibody","url":"https://stock-news.laohu8.com/highlight/detail?id=1158828817","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1158828817?lang=en_us&edition=fundamental","pubTime":"2026-02-23 09:50","pubTimestamp":1771811417,"startTime":"0","endTime":"0","summary":"HBM HOLDINGS-B (02142) saw its shares rise more than 8% during the morning trading session. At the time of writing, the stock was up 7.92%, trading at HK$13.21 with a turnover of HK$217.947 million....","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02142","VT","BK1574","BK4585","VXUS","BK4588","BK1161","BK1583"],"gpt_icon":0},{"id":"1167405741","title":"CStone Pharma-B's PD-L1 Antibody Sugemalimab Gains UK Approval for Advanced Lung Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=1167405741","media":"Stock News","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1167405741?lang=en_us&edition=fundamental","pubTime":"2026-02-23 08:20","pubTimestamp":1771806029,"startTime":"0","endTime":"0","summary":"CStone Pharmaceuticals-B (02616) announced that its new indication application for sugemalimab has been approved by the UK Medicines and Healthcare products Regulatory Agency (MHRA). The approval...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["III","BK1161","02616","BK4134","BK1574"],"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":1,"totalSize":120,"code":"91000000","status":"200"}]}}